 |
|
Spring Meeting Trial Reports:
2011 /
2010 /
2009
|
| ID |
Study Title |
Status |
|
IND.172 |
Phase II Study of Bortezomib and Gemcitabine in Patients with Relapsed Mantle Cell Lymphoma
MORE... |
Closed |
|
IND.182 |
A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in
Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
MORE... |
Closed |
|
IND.186 |
A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination With Low Dose ARA-C (Cytarabine)
In Elderly Patients With AML Or High-Risk MDS
MORE... |
Closed |
|
IND.191 |
A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma
MORE... |
Open |
|
IND.193 |
A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory
Chronic Lymphocytic Leukemia
MORE... |
Planned |
|
AL.3 |
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide (AS2O3)
(NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy with Intermittent Tretinoin vs
Intermittent Tretinoin plus Mercaptopurine and Methotrexate for Patients with Untreated Acute Promyelocytic Leukemia
MORE... |
Closed |
|
AL.4 |
A Multi-Center Phase II Study in Adults with Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically
Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol
MORE... |
Closed |
|
AL.5 |
A Phase II Study of Adult ALL Trial
MORE... |
Open |
|
ALC.1 |
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus
Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to
Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients
Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)
MORE... |
Closed |
|
ALC.2 |
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine)
and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in
Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
MORE... |
Closed |
|
CL.2 |
A Phase II Study of Oral Fludarabine Phosplate in Patients with Previously Untreated B-cell Chronic Lymphocytic
Leukemia
MORE... |
Permanently Closed |
|
CL.3 |
A Genetic, Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients
with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia
MORE... |
Open |
|
CLC.1 |
A Phase III Intergroup CLL Study Of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to
Early Intervention versus Observation with Later Treatment in the High Risk Genetic Subset
with IGVH Unmutated Disease
MORE... |
Closed |
|
CM.1 |
A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for or Dasatinib (BMS 354825)
(NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase
MORE... |
Closed |
|
HD.6 |
A Phase III Study of Radiotherapy or ABVD plus Radiotherapy versus ABVD Alone in the Treatment of Early Stage Hodgkin's
Disease
MORE... |
Permanently Closed |
|
HD.7 |
A Randomized Phase III Trial of ABVD versus Stanford V with or without Radiation Therapy in Locally Extensive and
Advanced Stage Hodgkin's Disease
MORE... |
Closed |
|
HD.8 |
BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's lymphoma
MORE... |
Closed |
|
LY.7 |
Chimeric Anti-CD20 Monoclonal Antibody (Rituximab)in Remission Induction and Maintenance Treatment of Relapsed
Follicular Non-Hodgkins Lymphoma. A Phase III Randomized Clinical Trial
MORE... |
Closed |
|
LY.9 |
Randomised Intergroup Trial of First Line Treatment for Patients with Diffuse Large B-Cell Non-Hodgkins Lymphoma with
a CHOP-like Chemotherapy Regimen with or without the Anti-CD20 Antibody Rituximab (IDEC-C2B8)
MORE... |
Closed |
|
LY.10 |
A Phase II Study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) in Patients with Either Hodgkin's Disease or
Aggressive Histology Non-Hodgkin's Lymphoma Which Is Relapsed or Refractory
MORE... |
Permanently Closed |
|
LY.11 |
A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to
Conventional Dose CHOP Chemotherapy plus Rituximab for CD20+B-Cell Lymphomas (with Possible Late Autologous Stem Cell
Transplant)for Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate/High Risk
International Classification Prognostic Groups
MORE... |
Closed |
|
LY.12 |
A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin
plus/minus Rituximab as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology
Non-Hodgkin'sLymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab
versus Observation
MORE... |
Closed |
|
LY.13 |
A Multi-centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide,
Vincristine, Prednisone and Rituximab (BCVP-R) for Patients with Advanced Stage Follicular Non-Hodgkin's Lymphoma
Requiring Systemic First-Line Treatment
MORE... |
Permanently Closed |
|
MY.7 |
A Comparative Study of Dexamethasone versus Prednisone (Both In Combination with Melphalan) As Induction Therapy in
Untreated Symptomatic Myeloma with an Additional Assessment of Dexamethasone versus No Additional Treatment as
Maintenance Therapy
MORE... |
Permanently Closed |
|
MY.10 |
A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell
Transplant in Patients with Multiple Myeloma
MORE... |
Closed |
|
MY.11 |
A Randomized Phase II Dose Finding Study of Lenalidomide and Melphalan in Patients with Previously Untreated Multiple
Myeloma
MORE... |
Permanently Closed |
